Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$3.04 +5.4%	$2.23	$0.80 ▼ $3.14	$797.10M	0.88	2.92 million shs	3.94 million shs
IMNM Immunome	$8.86 +2.7%	$7.60	$5.15 ▼ $16.81	$774.84M	2	915,886 shs	117,994 shs
NRIX Nurix Therapeutics	$10.71 +6.7%	$10.45	$8.18 ▼ $29.56	$817.10M	2.23	870,663 shs	216,378 shs
SLS SELLAS Life Sciences Group	$1.74 -2.5%	$1.41	$0.77 ▼ $2.12	$174.11M	2.34	1.51 million shs	812,176 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	-1.37%	+2.49%	+18.52%	+57.38%	+169.16%
IMNM Immunome	+0.35%	+8.96%	+0.58%	-2.92%	-40.97%
NRIX Nurix Therapeutics	+2.76%	+2.66%	-12.47%	-33.07%	-35.39%
SLS SELLAS Life Sciences Group	-7.77%	+4.71%	+26.24%	+56.14%	+28.99%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKBA Akebia Therapeutics	4.033 of 5 stars	4.6	1.0	4.0	2.6	0.0	0.6
IMNM Immunome	3.2184 of 5 stars	4.5	2.0	0.0	3.4	2.5	0.0
NRIX Nurix Therapeutics	1.8654 of 5 stars	4.4	0.0	0.0	2.3	0.8	0.0
SLS SELLAS Life Sciences Group	0.4767 of 5 stars	0.0	1.0	0.0	4.4	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKBA Akebia Therapeutics	3.20	Buy	$6.63	118.29% Upside
IMNM Immunome	3.00	Buy	$23.33	163.36% Upside
NRIX Nurix Therapeutics	2.84	Moderate Buy	$30.44	184.31% Upside
SLS SELLAS Life Sciences Group	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SLS, AKBA, NRIX, and IMNM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/13/2025	IMNM Immunome	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$33.00 ➝ $21.00
4/29/2025	NRIX Nurix Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00 ➝ $27.00
4/28/2025	AKBA Akebia Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/28/2025	AKBA Akebia Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00
4/9/2025	NRIX Nurix Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$32.00 ➝ $25.00
4/9/2025	NRIX Nurix Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $35.00
4/9/2025	NRIX Nurix Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $27.00
4/4/2025	AKBA Akebia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.50 ➝ $7.50
4/2/2025	IMNM Immunome	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$23.00
4/2/2025	NRIX Nurix Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00 ➝ $36.00
4/1/2025	AKBA Akebia Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKBA Akebia Therapeutics	$184.91M	4.31	N/A	N/A	($0.16) per share	-18.97
IMNM Immunome	$10.94M	70.48	N/A	N/A	$2.77 per share	3.20
NRIX Nurix Therapeutics	$56.42M	14.47	N/A	N/A	$7.44 per share	1.44
SLS SELLAS Life Sciences Group	$1M	173.11	N/A	N/A	($0.25) per share	-6.94

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKBA Akebia Therapeutics	-$51.92M	-$0.21	N/A	N/A	N/A	-27.07%	N/A	-20.57%	8/14/2025 (Estimated)
IMNM Immunome	-$106.81M	-$3.18	N/A	N/A	N/A	-3,014.59%	-48.63%	-41.62%	8/11/2025 (Estimated)
NRIX Nurix Therapeutics	-$193.57M	-$2.80	N/A	N/A	N/A	-354.85%	-53.65%	-38.59%	7/10/2025 (Estimated)
SLS SELLAS Life Sciences Group	-$37.34M	-$0.38	N/A	N/A	N/A	N/A	-629.46%	-178.65%	8/12/2025 (Estimated)

Latest SLS, AKBA, NRIX, and IMNM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	SLS SELLAS Life Sciences Group	-$0.1067	-$0.07	+$0.0367	-$0.07	N/A	N/A
5/12/2025	Q1 2025	IMNM Immunome	-$0.66	-$0.52	+$0.14	-$0.52	$0.46 million	$2.93 million
5/8/2025	Q1 2025	AKBA Akebia Therapeutics	-$0.03	$0.03	+$0.06	$0.03	$44.88 million	$57.34 million
4/8/2025	Q1 2025	NRIX Nurix Therapeutics	-$0.72	-$0.67	+$0.05	-$0.67	$12.78 million	$18.45 million
3/20/2025	Q4 2024	SLS SELLAS Life Sciences Group	-$0.1067	-$0.08	+$0.0267	-$0.08	N/A	N/A
3/19/2025	Q4 2024	IMNM Immunome	-$0.68	-$0.84	-$0.16	-$1.28	$3.07 million	$2.74 million
3/13/2025	Q4 2024	AKBA Akebia Therapeutics	-$0.05	-$0.10	-$0.05	-$0.10	$37.36 million	$46.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
IMNM Immunome	N/A	N/A	N/A	N/A	N/A
NRIX Nurix Therapeutics	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKBA Akebia Therapeutics	N/A	1.52	1.21
IMNM Immunome	N/A	6.17	6.17
NRIX Nurix Therapeutics	N/A	6.46	6.46
SLS SELLAS Life Sciences Group	N/A	2.26	2.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKBA Akebia Therapeutics	33.92%
IMNM Immunome	44.58%
NRIX Nurix Therapeutics	N/A
SLS SELLAS Life Sciences Group	17.38%

Insider Ownership

Company	Insider Ownership
AKBA Akebia Therapeutics	3.00%
IMNM Immunome	8.60%
NRIX Nurix Therapeutics	7.40%
SLS SELLAS Life Sciences Group	1.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKBA Akebia Therapeutics	430	262.64 million	209.24 million	Optionable
IMNM Immunome	40	87.01 million	72.92 million	Optionable
NRIX Nurix Therapeutics	300	76.24 million	70.42 million	Optionable
SLS SELLAS Life Sciences Group	10	99.78 million	69.54 million	Not Optionable

SLS, AKBA, NRIX, and IMNM Headlines

Recent News About These Companies

594,919 Shares in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Bought by Brooklyn FI LLC

May 28 at 6:12 AM | marketbeat.com

SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase

May 20, 2025 | globenewswire.com

SELLAS Life Sciences Group, Inc. Common Stock

May 16, 2025 | fxempire.com

Sellas doses first paediatric subject with AML in Phase II trial of SLS009

May 16, 2025 | msn.com

SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML

May 15, 2025 | finanznachrichten.de

SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML

May 15, 2025 | globenewswire.com

SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 13, 2025 | globenewswire.com

SELLAS Life Sciences Group (SLS) to Release Earnings on Tuesday

May 8, 2025 | marketbeat.com

Anson Funds Management LP Has $1.24 Million Holdings in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)

May 5, 2025 | marketbeat.com

SELLAS Life Sciences Group, Inc. Presents Promising Preclinical Data on SLS009 for TP53 Mutated Acute Myeloid Leukemia at AACR 2025

April 28, 2025 | quiverquant.com

SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference

April 28, 2025 | globenewswire.com

Why SELLAS Life Sciences Group, Inc.’s (SLS) Stock Is Up 8.95%

April 26, 2025 | aaii.com

SELLAS Life Sciences Group, Inc. to Present Preclinical Efficacy Data for SLS009 in ASXL1 Mutated Colorectal Cancer at ASCO 2025 Annual Meeting

April 23, 2025 | quiverquant.com

SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

April 23, 2025 | globenewswire.com

Sellas Life Sciences announces OS data in Cohort 3 from Phase 2 SLS009 trial

April 9, 2025 | markets.businessinsider.com

SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML

April 8, 2025 | globenewswire.com

SELLAS Life Sciences Group, Inc. Common Stock (SLS) Insider Activity

March 30, 2025 | nasdaq.com

SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update

March 21, 2025 | finanznachrichten.de

SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update

March 20, 2025 | globenewswire.com

Sellas reports Phase IIa trial data of SLS009 for DLBCL treatment

February 21, 2025 | msn.com

SELLAS Life Sciences Group, Inc.: SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL

February 20, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLS, AKBA, NRIX, and IMNM Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

$3.04 +0.16 (+5.38%)

As of 11:57 AM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Immunome NASDAQ:IMNM

$8.86 +0.23 (+2.67%)

As of 11:57 AM Eastern

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Nurix Therapeutics NASDAQ:NRIX

$10.71 +0.67 (+6.65%)

As of 11:58 AM Eastern

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

SELLAS Life Sciences Group NASDAQ:SLS

$1.74 -0.05 (-2.53%)

As of 11:58 AM Eastern

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time